Non-diabetic patients had a 27% reduced risk of heart failure, and AZ published a net detailed Phase 3 result for Dagly

AstraZeneca has published detailed results from its SGLT2 inhibitor Farxiga (dapagliflozin) in a Phase 3 clinical trial for patients with heart failure at the Annual Meeting of the European Society of Cardiology (ESC2019). In August, AstraZeneta announced that Dagrid had reached a major and critical secondary end in the trial. The published detailed results show that Daglysse net reduces the risk of cardiovascular death and heart failure in non-type 2 diabetes patients with the same effect as type 2 diabetes patients, providing strong evidence for further expansion of Daglie net suitable patient population.
Heart failure is a life-threatening and serious illness caused by the heart's inability to pump enough blood through the body. There are about 64 million patients in the world (half of whom are in the type of drop in blood test scores), and nearly half die within five years of diagnosis. Heart failure is one of the leading causes of hospitalization for people over 65 years of age and represents a serious clinical and economic burden.
Dagledon is a "first-in-class" oral SGLT2 inhibitor. It has been approved by the FDA to improve blood sugar control in people with type 2 diabetes, together with diet and exercise, and can lower their weight and blood pressure. It is also approved by the European Union for the treatment of people with type 1 diabetes.
DAPA-HF is the first Phase 3 clinical trial to study the risk of death and disease increase caused by SGLT2 inhibitors and heart failure. The patients in the group represented typical heart failure patients, with 45 percent having type 2 diabetes at the baseline state prior to treatment. In this randomized double-blind, multi-center, international Phase 3 clinical trial, patients with reduced shot blood score were treated with daglib or placebo in addition to standard therapy. The main compound endpoints of the trial were heart failure exacerbation events (defined as hospitalization or emergency heart failure) or cardiovascular death.Detailed data published in ESC2019 show that Dagrid was able to reduce the risk of heart failure exacerbation events and cardiovascular death in patients with heart failure by 26% (HR-0.74, 95% CI:0.65, 0.85, p-0.00001), including a 30% reduction in the risk of heart failure and an 18% reduction in the risk of cardiovascular death. At the same time, an assessment of the symptoms of heart failure reported by patients using the KCCG symptom scale showed that Dagle net was able to significantly improve the reported symptoms of heart failure in patients.
New drugs of the SGLT2 inhibitor type have shown a reduced risk of heart failure in diabetic patients, so the industry is concerned about the net performance of Dagled in non-diabetic patients. Detailed subgroup results published showed that Dagrid was able to reduce the risk of heart failure by 27% (HR=0.73,95% CI:0.60,0.88) in patients with type 2 diabetes (HR=0.75,95% CI:0.63,0.90).
"Farxiga has shown good results in treating type 2 diabetes," said Dr. Mene Pangalos, Executive Vice President, Biopharmaceutical Research and Development, AstraZenega. And these exciting new findings show its potential to reduce the burden of heart failure in people with or without type 2 diabetes. " (Drug Mingkang)